Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSide effects tend to return or intensify each time your Mounjaro dose goes up. That is normal, expected, and — for most people — short-lived. Each new pen delivers a higher amount of tirzepatide, and your digestive system needs a few days to recalibrate. Nausea, loose stools and fatigue are the most commonly reported symptoms in the days following a dose increase, according to the NHS guidance on tirzepatide. These are prescription-only medicines; a prescriber assesses your whole picture before any increase is recommended, which is why clinical oversight matters at every step.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Mounjaro works by activating two gut-hormone receptors (GIP and GLP-1) that slow how quickly your stomach empties and signal fullness to your brain. The licensed schedule begins at 2.5 mg, a dose whose main job is to help your body adjust rather than produce significant weight loss. From there, the prescriber typically moves through 5 mg, 7.5 mg, 10 mg, 12.5 mg and up to 15 mg, usually in four-week steps.
Each increase is effectively a new challenge for your digestive system. Your gut's response to higher receptor activation is broadly the same as when you started, just compressed into a shorter adjustment window because your body already has some familiarity with the medicine. That is why patients who sailed through 2.5 mg sometimes find 7.5 mg or 10 mg noticeably harder going. It does not mean the medicine is harming you. It means the dose is doing something.
If you want a detailed look at what moving between specific strengths involves in practice, our guide to increasing your Mounjaro dose covers the titration process step by step.
Across the SURMOUNT clinical programme, gastrointestinal symptoms were the most commonly reported effects, and they peaked around dose changes. Nausea tops the list, sometimes arriving within hours of the injection, sometimes the next morning. Alongside it come loose stools or diarrhoea, constipation (which can follow if diarrhoea comes first), indigestion, burping and a feeling of fullness that makes it hard to eat a normal-sized meal. Fatigue, mild headache and dizziness also appear with some regularity after step-ups.
The practical rhythm most people describe: the first day or two after the new dose feels roughest, then things gradually ease. By the end of the first week, many people are eating reasonably normally again. By week three or four, the new dose tends to feel unremarkable, until the next increase.
Smaller meals, eaten slowly, make a real difference. So does avoiding rich or very fatty food in the days around injection day. Adequate water intake matters too, especially if nausea is reducing your appetite for both food and drinks. For a closer look at what people experience at one of the more commonly discussed strengths, this page on 5 mg side effects covers that particular transition in more depth.
One thing our prescribers hear often: people wonder whether a faster heartbeat after a dose change is something to worry about. There is a straightforward explanation for the heart rate question that is worth reading if you have noticed it.
Most dose-related side effects are unpleasant but not dangerous. A subset, though, needs prompt attention.
Pancreatitis is the one that warrants the clearest warning. In January 2026 the MHRA issued a formal Drug Safety Update highlighting acute pancreatitis as an infrequent but potentially serious effect of GLP-1 medicines including tirzepatide. The symptoms to act on immediately: severe stomach pain that does not ease up, which may radiate through to your back, with or without vomiting. Do not wait to see if it passes. Go to A&E or call 999.
Other situations that need medical attention fairly quickly (not necessarily emergency-level but certainly the same day or next day) include signs of dehydration from prolonged vomiting or diarrhoea (very dark urine, dizziness on standing, inability to keep fluids down), a suspected allergic reaction such as swelling of the face or throat, or low mood and thoughts of self-harm, which have been reported in post-marketing data and should be discussed with your GP or prescriber without delay.
Gallbladder problems (pain in the upper right abdomen, sometimes with nausea and fever) are also associated with rapid weight loss on GLP-1 medicines more broadly. Tell your prescriber if you notice this pattern.
If you are uncertain whether what you are experiencing is normal adjustment or something to flag, contact your prescriber. Our team is available seven days a week (reach us through the contact page) and if something feels genuinely urgent, treat it as urgent.
Timing a dose increase is not purely mechanical. A good prescriber looks at how you have tolerated the current dose, whether your weight response suggests the current level still has room to work, and whether any health changes shift the risk-benefit calculation. That assessment happens before every step-up, not just at the start.
If side effects at a new dose are severe or persistent, a prescriber may recommend staying at the current strength for longer rather than pushing to the next pen, and our page on what to expect from Mounjaro dose increase side effects goes into more detail on what is considered normal versus worth flagging. Reducing the dose is also an option in some circumstances. These are clinical decisions, the Patient Information Leaflet and your prescriber's guidance are the right places to find advice specific to your situation, not the titration schedule alone.
The MHRA's Yellow Card scheme lets you report any suspected side effect directly, including ones that feel mild but persistent. Reporting helps build the post-marketing safety picture for a medicine that still carries a Black Triangle (▼) designation, meaning it is under additional monitoring. It takes only a few minutes.
For context on the medicine more broadly, our Mounjaro overview page covers licensing, how it works and what clinical trials showed about its effects. Our prescribers discuss both suitability and the expected side-effect pattern as part of every consultation, and if you would like a fuller picture of how the process works in practice, our guide to increasing your tirzepatide dose walks through the clinical reasoning behind each step-up. If you are considering treatment or thinking about a dose change, starting a free consultation is the natural first step. The clinical team behind nume reviews every case personally.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.